{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Mahwah",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "84516",
      "recalling_firm": "Glenmark Pharmaceuticals Inc., USA",
      "address_1": "750 Corporate Dr",
      "address_2": "N/A",
      "postal_code": "07430-2009",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Natiowide",
      "recall_number": "D-0640-2020",
      "product_description": "Glenmark Ranitidine Tablets USP 150 mg Rx Only 100 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ   NDC 68462-248-01",
      "product_quantity": "217,956 bottles",
      "reason_for_recall": "CGMP Deviations: Presence of NDMA impurity detected in product.",
      "recall_initiation_date": "20191217",
      "center_classification_date": "20200105",
      "report_date": "20200115",
      "code_info": "7701033A  7701826A  7702344A  7702345A  7702489A  7702706A  7702707A  7702708A  7702858A  7702859A  7702860A  7702928A  7702929A  7703196A  7703634A  7704492A  7704493A  7705159A  19190289  19190342  19190372"
    }
  ]
}